Acadia Pharmaceuticals | ACAD - Ordinary Share Capital


Acadia Pharmaceuticals reported $172.31M in Ordinary Share Capital for its fiscal quarter ending in September of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 172.31M 174K Sep/2026
ALKERMES USD 168.03M 489K Sep/2026
Alnylam Pharmaceuticals USD 133.88M 141K Sep/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.68M 141K Sep/2026
Bristol-Myers Squibb USD 2.04B 7M Jun/2026
Cara Therapeutics USD 9.38M 2.01K Mar/2026
Corcept Therapeutics USD 109.36M 1.44M Sep/2026
Cytokinetics USD 138.76M 14.33M Jun/2026
Eisai JPY 282.46M 0 Sep/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Incyte USD 200.98M 1.03M Jun/2026
J&J USD 2.41B 1.64M Jun/2026
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 101.3M 750K Sep/2026
Pfizer USD 5.7B 1000K Sep/2026
Prothena USD 51.74M 1.33M Jun/2026
PTC Therapeutics USD 83.33M 445K Jun/2026
Sarepta Therapeutics USD 107.23M 1.61M Sep/2026
Ultragenyx Pharmaceutical USD 98.6M 300K Jun/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024
Vertex Pharmaceuticals USD 253.5M 200K Sep/2026